Additive Orthopaedics® Announces FDA Approval of Patient Specific Talus Spacer, First Approved in the U.S.
(MENAFN - PR Newswire) LITTLE SILVER, N.J., Feb. 17, 2021 /PRNewswire/ --Â Additive Orthopaedics, LLC., announced today it has received an approval order from the U.S. Food and Drug Administration ("FDA") for its Humanitarian Device Exemption ("HDE") application for the Patient Specific Talus Spacer for treatment of avascular necrosis of the talus. The approval order makes the Additive Orthopaedics Patient Specific Talus Spacer the first and only patient specific total talus replacement implant approved by the FDA for use in the United States. Continue Reading (PRNewsfoto/Additive Ortho...